Sustainability | September 17, 2024
Piramal Pharma's GHG Commitment Validated and Approved by SBTi
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
The acquisition is based on an enterprise value of Rs. 1,660 crore
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
Subscribe To Our Newsletter & Stay Updated
